Format

Send to

Choose Destination
Leuk Lymphoma. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. Epub 2015 Oct 15.

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.

Author information

1
a NCIC Clinical Trials Group, Queen's University , Kingston , ON , Canada .
2
b Department of Biology , University of New Brunswick , Saint John , NB , Canada .
3
c Department of Medicine , Dalhousie University , Saint John , NB , Canada .
4
d Juravinski Cancer Centre , Hamilton , ON , Canada .
5
e Department of Medicine, Division of Hematology , University of Alberta , Edmonton , AB , Canada .
6
f Department of Medical Oncology and Hematology , Princess Margaret Cancer Centre , Toronto , ON , Canada .
7
g Division of Hematology and Hematologic Malignancies , University of Calgary , Calgary , AB , Canada .
8
h Astex Pharmaceuticals, Inc. , Dublin , CA , USA , and.
9
i Department of Oncology, Saint John Regional Hospital and Department of Medicine , Dalhousie University , Saint John , NB , Canada.
PMID:
26376958
DOI:
10.3109/10428194.2015.1091927
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center